Details

Autor(en) / Beteiligte

• Martin, Daniel S
• Shahid, Tasnin
• Gould, Doug W
• Richards-Belle, Alvin
• Doidge, James C
• Camsooksai, Julie
• Charles, Walton N
• Davey, Miriam
• Francis Johnson, Amelia
• Garrett, Roger M
• Grocott, Michael PW
• Jones, Joanne
• Lampro, Lamprini
• Miller, Lorna
• O’Driscoll, B Ronan
• Rostron, Anthony J
• Sadique, Zia
• Szakmany, Tamas
• Young, Paul J
• Rowan, Kathryn M
• Harrison, David A
• Mouncey, Paul R

Titel

Evaluating the clinical and cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in intensive care: Protocol for the UK-ROX trial

Ist Teil von

• Journal of the Intensive Care Society, 2024-05, Vol.25 (2), p.223-230

Ort / Verlag

London, England: SAGE Publications

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Background: In the United Kingdom, around 184,000 adults are admitted to an intensive care unit (ICU) each year with over 30% receiving mechanical ventilation. Oxygen is the commonest therapeutic intervention provided to these patients but it is unclear how much oxygen should be administered for the best clinical outcomes. Methods: The UK-ROX trial will evaluate the clinical and cost-effectiveness of conservative oxygen therapy (the minimum oxygen concentration required to maintain an oxygen saturation of 90% ± 2%) versus usual oxygen therapy in critically ill adults receiving supplemental oxygen when invasively mechanically ventilated in ICUs in England, Wales and Northern Ireland. The trial will recruit 16,500 patients from approximately 100 UK adult ICUs. Using a deferred consent model, enrolled participants will be randomly allocated (1:1) to conservative or usual oxygen therapy until ICU discharge or 90 days after randomisation. Objectives: The primary clinical outcome is all cause mortality at 90 days following randomisation. Discussion: The UK-ROX trial has received ethical approval from the South Central – Oxford C Research Ethics Committee (Reference: 20/SC/0423) and the Confidentiality Advisory Group (Reference: 22/CAG/0154). The trial commenced in May 2021 and, at the time of publication, 95 sites had opened to recruitment.